Investigative Magnetic Resonance Imaging

Korean Society of Magnetic Resonance in Medicine (대한자기공명의과학회)
권호 표지
DOI QR코드

DOI QR Code

Factors Influencing the Background Parenchymal Enhancement in Follow-Up Breast MRI after Adjuvant Endocrine Therapy

  • Youk, Ji Hyun (Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Son, Eun Ju (Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Kim, Jeong-Ah (Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine)
  • Received : 2015.05.12
  • Accepted : 2015.06.16
  • Published : 2015.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To investigate factors influencing the evaluation of background parenchymal enhancement (BPE) at follow-up breast magnetic resonance imaging (MRI) after adjuvant endocrine therapy. Materials and Methods: One hundred twelve women with breast cancer and MRI of the contralateral unaffected breast before and after endocrine therapy were identified. Two readers in consensus performed blinded side-by-side comparison of BPE (minimal, mild, moderate, and marked) before and after therapy with categorical scales. Age, body mass index, menopausal status, treatment regimen (selective estrogen receptor modulator or aromatase inhibitor), chemotherapy, follow-up duration, BPE at baseline MRI, MRI field strength before and after therapy, and recurrence were analyzed for their influences on decreased BPE. Results: Younger age, premenopausal status, treatment with selective estrogen receptor modulator, MRI field strength, and moderate or marked baseline BPE were significantly associated with decreased BPE. In multivariate analysis, MRI field strength and baseline BPE showed a significant association. Conclusion: MRI field strength and baseline BPE before and after therapy .were associated with decreased BPE at post-therapy, follow-up MRI.

Keywords

References

  1. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009;9:631-643 https://doi.org/10.1038/nrc2713
  2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-784 https://doi.org/10.1016/S0140-6736(11)60993-8
  3. Cuzick J. Breast density predicts endocrine treatment outcome in the adjuvant setting. Breast Cancer Res 2012;14:109 https://doi.org/10.1186/bcr3235
  4. Kim J, Han W, Moon HG, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res 2012;14:R102 https://doi.org/10.1186/bcr3221
  5. Brennan S, Liberman L, Dershaw DD, Morris E. Breast MRI screening of women with a personal history of breast cancer. AJR Am J Roentgenol 2010;195:510-516 https://doi.org/10.2214/AJR.09.3573
  6. Mousa NA, Eiada R, Crystal P, Nayot D, Casper RF. The effect of acute aromatase inhibition on breast parenchymal enhancement in magnetic resonance imaging: a prospective pilot clinical trial. Menopause 2012;19:420-425 https://doi.org/10.1097/gme.0b013e31823772a8
  7. King V, Goldfarb SB, Brooks JD, et al. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging. Radiology 2012;264:670-678 https://doi.org/10.1148/radiol.12112669
  8. Kuhl CK, Bieling HB, Gieseke J, et al. Healthy premenopausal breast parenchyma in dynamic contrastenhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 1997;203:137-144 https://doi.org/10.1148/radiology.203.1.9122382
  9. Muller-Schimpfle M, Ohmenhauser K, Stoll P, Dietz K, Claussen CD. Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 1997;203:145-149 https://doi.org/10.1148/radiology.203.1.9122383
  10. Chen JH, Yu H, Lin M, Mehta RS, Su MY. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI. Magn Reson Imaging 2013;31:1465-1471 https://doi.org/10.1016/j.mri.2013.07.014
  11. Pfleiderer SO, Sachse S, Sauner D, et al. Changes in magnetic resonance mammography due to hormone replacement therapy. Breast Cancer Res 2004;6:R232-238 https://doi.org/10.1186/bcr779
  12. Delille JP, Slanetz PJ, Yeh ED, Kopans DB, Halpern EF, Garrido L. Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging--initial observations. Radiology 2005;235:36-41 https://doi.org/10.1148/radiol.2351040012
  13. Eng-Wong J, Orzano-Birgani J, Chow CK, et al. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:1696-1701 https://doi.org/10.1158/1055-9965.EPI-07-2752
  14. Oksa S, Parkkola R, Luukkaala T, Maenpaa J. Breast magnetic resonance imaging findings in women treated with toremifene for premenstrual mastalgia. Acta Radiol 2009;50:984-989 https://doi.org/10.3109/02841850903168083
  15. King V, Kaplan J, Pike MC, et al. Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. Breast J 2012;18:527-534 https://doi.org/10.1111/tbj.12002
  16. Schrading S, Schild H, Kuhr M, Kuhl C. Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study. Radiology 2014;271:45-55 https://doi.org/10.1148/radiol.13131198
  17. Morris E, Comstock CE, Lee CH, et al. ACR BI-RADS magnetic resonance imaging. In ACR BI-RADS atlas, breast imaging reporting and data system. Reston, VA: American College of Radiology, 2013
  18. Morris EA. Diagnostic breast MR imaging: current status and future directions. Radiol Clin North Am 2007;45:863-880, vii https://doi.org/10.1016/j.rcl.2007.07.002
  19. Uematsu T, Kasami M, Watanabe J. Background enhancement of mammary glandular tissue on breast dynamic MRI: imaging features and effect on assessment of breast cancer extent. Breast Cancer 2012;19:259-265 https://doi.org/10.1007/s12282-011-0279-0
  20. Cubuk R, Tasali N, Narin B, Keskiner F, Celik L, Guney S. Correlation between breast density in mammography and background enhancement in MR mammography. Radiol Med 2010;115:434-441 https://doi.org/10.1007/s11547-010-0513-4
  21. Harris JR, Lippman ME, Morrow M, Osborne CK. Disease of the breast. Philadelphia, PA: Lippincott Williams & Wilkins, 2010
  22. Raza S. Implementing a breast MR imaging program: all things considered. Magn Reson Imaging Clin N Am 2010;18:187-198, vii https://doi.org/10.1016/j.mric.2010.02.010
  23. Rahbar H, Partridge SC, DeMartini WB, Thursten B, Lehman CD. Clinical and technical considerations for high quality breast MRI at 3 Tesla. J Magn Reson Imaging 2013;37:778-790 https://doi.org/10.1002/jmri.23834
  24. Chatterji M, Mercado CL, Moy L. Optimizing 1.5-Tesla and 3-Tesla dynamic contrast-enhanced magnetic resonance imaging of the breasts. Magn Reson Imaging Clin N Am 2010;18:207-224, viii https://doi.org/10.1016/j.mric.2010.02.011
  25. Kuhl CK, Jost P, Morakkabati N, Zivanovic O, Schild HH, Gieseke J. Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. Radiology 2006;239:666-676 https://doi.org/10.1148/radiol.2392050509
  26. Pinker K, Grabner G, Bogner W, et al. A combined high temporal and high spatial resolution 3 Tesla MR imaging protocol for the assessment of breast lesions: initial results. Invest Radiol 2009;44:553-558 https://doi.org/10.1097/RLI.0b013e3181b4c127
  27. Rakow-Penner R, Daniel B, Yu H, Sawyer-Glover A, Glover GH. Relaxation times of breast tissue at 1.5T and 3T measured using IDEAL. J Magn Reson Imaging 2006;23:87-91 https://doi.org/10.1002/jmri.20469